Evidence map›Paper›PMID 31817924›Full record

ArticleCancers2019

The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex.

Toufic Kassouf, Romain Maxime Larive, Anne Morel, Serge Urbach, Nadir Bettache, Ma Cleofas Marcial Medina, Fabrice Mèrezègue, Gilles Freiss, Marion Peter, Florence Boissière-Michot and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Discovery of Potent EGFR Inhibitors WithFrontiers in pharmacology · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Toufic KassoufIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.ORCID 0000-0001-6011-880X
Romain Maxime LariveIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.ORCID 0000-0001-8479-209X
Anne MorelCRBM, CNRS, Univ Montpellier, 1919 Route de Mende, 34293 Montpellier, France.
Serge UrbachFunctional Proteomics Platform, IGF, Univ Montpellier, CNRS, INSERM, 141 rue de la Cardonille, 34094 Montpellier, France.
Nadir BettacheIBMM, Univ Montpellier, CNRS, ENSCM, 15 avenue Charles Flahault - BP 14491, 34093 Montpellier, France.ORCID 0000-0001-5426-7024
Ma Cleofas Marcial MedinaCinvestav-IPN, Cell Biology Department, Av. IPN # 2508, Mexico City 07360, Mexico.
Fabrice MèrezègueBioMV Dpt., Univ Montpellier CC25000, Place Eugène Bataillon, 34095 Montpellier, France.
Gilles FreissIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.
Marion PeterIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.ORCID 0000-0002-5720-4798
Florence Boissière-MichotUnité de Recherche Translationnelle, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.
Jérôme SolassolIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.
Philippe MontcourrierIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.
Peter CoopmanIRCM, Inserm, CNRS, Univ Montpellier, ICM, 208 Rue des Apothicaires, 34298 Montpellier, France.ORCID 0000-0003-3720-523X
Centre National de la Recherche Scientifique · FRÉcole Nationale Supérieure de Chimie de Montpellier · FRInstituto Politécnico Nacional · MXUniversité de Montpellier · FR

Funding

Fondation ARC pour la Recherche sur le Cancer SL220110603480Ligue Contre le Cancer 3FI12843RFBNPlan Cancer/ ITMO Cancer/Aviesan ASC14021FSARéseau National des Génopoles / ICS IR2283/K504
6 · The paper itself

Abstract

While first discovered in immunoreceptor signaling, the Syk protein kinase behaves as a tumor and metastasis suppressor in epithelial cells. Its reduced expression in breast and other carcinomas is correlated with decreased survival and increased metastasis risk, but its action mechanism remains largely unknown. Using phosphoproteomics we found that Syk phosphorylated E-cadherin and α-, β-, and p120-catenins on multiple tyrosine residues that concentrate at intercellular junctions. Increased Syk expression and activation enhanced E-cadherin/catenin phosphorylation, promoting their association and complex stability. In human breast cancer cells, Syk stimulated intercellular aggregation, E-cadherin recruitment and retention at adherens junctions, and promoted epithelial integrity, whereas it inhibited cell migration and invasion. Opposite effects were obtained with Syk knockdown or non-phosphorylatable mutant E-cadherin expression. Mechanistically, Syk stimulated the interaction of the E-cadherin/catenin complex with zonula occludens proteins and the actin cytoskeleton. Conditional Syk knockout in the lactating mouse mammary gland perturbed alveologenesis and disrupted E-cadherin localization at adherens junctions, corroborating the observations in cells. Hence, Syk is involved in the maintenance of the epithelial integrity of the mammary gland via the phosphorylation and stabilization of the E-cadherin/catenin adherens junction complex, thereby inhibiting cell migration and malignant tumor invasion.

Indexed as

breast cancerE-cadherinintercellular adhesionprotein tyrosine kinasetumor invasiontumor suppressor

Identifiers

PMID31817924
PMCPMC6966528
OpenAlexW2992048568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.